Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30015003 | 1.00 | TYRO3 (0.47) | TYRO3TSHRALDH1A1BRAFSMN1; SMN2 | |
| SCHEMBL23535610 | 0.90 | NPC1 (0.49) | TSHRALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL23535583 | 0.88 | TSHR (0.53) | TSHRALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL23535565 | 0.86 | TSHR (0.62) | TYRO3TSHRALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL23535585 | 0.81 | SMN1; SMN2 (0.55) | TSHRALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL23535552 | 0.79 | ALDH1A1 (0.52) | TSHRALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL16495574 | 0.75 | TSHR (0.59) | TSHRALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL23535523 | 0.74 | FYN (0.49) | — | |
| SCHEMBL23535518 | 0.74 | FYN (0.45) | — | |
| SCHEMBL16495441 | 0.72 | TSHR (0.66) | TSHRALDH1A1SMN1; SMN2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056497-A1 | CD206 Modulators Their Use and Methods for Preparation | US HEALTH (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2021126923-A1 | CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126923-A1 | CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056497-A1 | CD206 Modulators Their Use and Methods for Preparation | CD209, MSR1, ARG1 | TYRO3 583/4885TSHR 457/4885ALDH1A1 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.